Virtu Financial LLC Immunovant, Inc. Transaction History

Virtu Financial LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$18.55 - $39.96 $78,466 - $169,030	4,230 Added 40.44%	14,691 $564,000
Q2 2023 Jul 27, 2023	BUY	$14.2 - $23.75 $148,546 - $248,448	10,461 New	10,461 $198,000
Q2 2022 Aug 09, 2022	SELL	$3.38 - $5.65 $71,825 - $120,062	-21,250 Closed	0 $0
Q1 2022 May 17, 2022	BUY	$5.06 - $8.77 $32,060 - $55,566	6,336 Added 42.48%	21,250 $117,000
Q4 2021 Feb 17, 2022	BUY	$7.33 - $9.32 $109,319 - $138,998	14,914 New	14,914 $127,000
Q1 2021 May 19, 2021	SELL	$13.08 - $49.6 $83,515 - $316,696	-6,385 Closed	0 $0
Q4 2020 Feb 24, 2021	BUY	$36.36 - $52.71 $232,158 - $336,553	6,385 New	6,385 $295,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.